Virios Therapeutics

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

At Virios Therapeutics, our mission is to develop novel therapies for rare genetic diseases, alleviate the suffering of people living with these diseases, and give doctors and families scientifically sound treatments that can change patients’ lives for the better.

Our vision is to become a leader in rare genetic diseases and to dramatically improve the lives of those afflicted. We strive for continued breakthroughs in science and technology and for accessibility to our therapies throughout the world.

Virios Therapeutics has been recognized numerous times for its commitment to furthering medical research in the field of rare genetic diseases. We are the proud recipients of the 2020 Nobel Prize in Medicine, the 2019 Breakthrough Prize in Life Sciences, and the 2018 Physics World Breakthrough Award.